Investing In The Future of British Columbia

BC Advantage Funds. Take Advantage!


Advantage offers everyone in BC the opportunity to invest in some of the Province's most promising life science, technology and clean technology companies.  Advantage investors receive a 30% refundable tax credit from the BC government on investments of up to $200,000 per year.


Our Mission

To maximize financial returns to our investors by investing in, and helping build, world class companies.


Our Advantages
BC Advantage Funds is a unique family of funds with a number of benefits over other funds and investment options, including:
  • Investment Strategy: Advantage's investment strategy is comprised of five essential elements. See Investment Strategy.
  • A Proven Track Record: Advantage's management team has a proven track record, including the very successful Advantage Life Science Fund I (recipient of the CVCA's "Deal of the Year" award in 2006).
  • The Mentor Model: Advantage has a rich network of experienced, successful entrepreneurs and business people. This network provides early-stage companies with a wealth of business experience and expertise

05/14/2012

Allon Therapeautics Announces Completion of $10-Million Private Placement

02/02/2012

Advantage Completes Additional Investments Totaling $1.5 Million into Motion Technology and Redlen Technologies

12/23/2011

Protox Announces Closing of Additional CDN $8.3 Investment By Warburg Pincus

10/04/2011

MSI Methylation Sciences Raises $19 Million in Series A Financing

05/18/2011

Allon Updates Progress of Pivotal Phase 2/3 Clinical Trial

11/19/2010

Protox Closes First $10 Million Tranche of Warburg Pincus Investment

06/17/2010

Aquinox Pharmaceuticals Completes US $25 Million Series B Financiing

04/29/2010

Protox Signs $75 Million License Agreement with Kissei for Commercialization of PRX302 in Japan for BPH and Prostate Disease

01/29/2010

Conasys Receives “Ready to Rocket” Recognition

01/26/2010

Allon Pilot Clinical Trial Initiated to Evaluate Davunetide in Tau-pathology Dementias

01/19/2010

Mobidia Announces Results from Live Network Test with Tier One European Carrier

STRUCTURED Fund

(CLOSED):

$7.90
(as at 05/11/2012)
 
Home | News | Disclaimer | Privacy Policy | Contact Us | Lions Capital Website
© 2008 BC Advantage Funds Vancouver Web Development by Graphically Speaking